New pancreatic cancer treatment is now Israeli

Normally, foreign investors acquire Israeli biotechs that develop cancer treatments. But here, Israel’s Redhill Biopharma has bought pancreatic cancer treatment RP101 from Germany’s RESprotect GmbH. RP101 has passed Phase II trials and has vital orphan status.
http://ir.redhillbio.com/releasedetail.cfm?ReleaseID=866033

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *